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Abstract Approximately 25 years ago the first computer
applications were conceived for the purpose of automated
‘de novo’ drug design, prominent pioneering tools being
ALADDIN, CAVEAT, GENOA, and DYLOMMS. Many
of these early concepts were enabled by innovative tech-
niques for ligand-receptor interaction modeling like GRID,
MCSS, DOCK, and CoMFA, which still provide the the-
oretical framework for several more recently developed
molecular design algorithms. After a first wave of software
tools and groundbreaking applications in the 1990s—
expressly GROW, GrowMol, LEGEND, and LUDI repre-
senting some of the key players—we are currently wit-
nessing a renewed strong interest in this field. Innovative
ideas for both receptor and ligand-based drug design have
recently been published. We here provide a personal per-
spective on the evolution of de novo design, highlighting
some of the historic achievements as well as possible future
developments of this exciting field of research, which
combines multiple scientific disciplines and is, like few
other areas in chemistry, subject to continuous enthusiastic
discussion and compassionate dispute.
Keywords Drug design  Computational chemistry 
Fragment-based design  De novo design
Introducton
Approximately 25 years ago the first computer applications
were conceived for the purpose of automated ‘‘de novo’’
drug design [1–4], prominent pioneering tools being
ALADDIN [5], CAVEAT [6, 7], GENOA [8], and DY-
LOMMS [9]. Many of these early concepts were enabled
by innovative techniques for ligand-receptor interaction
modeling like GRID [10], MCSS [11], DOCK [12], and
CoMFA [13], which still provide the theoretical framework
for several more recently developed molecular design
algorithms. After a first wave of software tools and
groundbreaking applications in the 1990s [14–18]—
expressly GROW [19], GrowMol [20], LEGEND [21, 22],
and LUDI [23, 24] representing some of the key players—
we are currently witnessing a renewed strong interest in
this field. Innovative ideas for both receptor- and ligand-
based drug design have recently been published [25, 26].
We here provide a personal perspective on the evolution of
de novo design, highlighting some of the historic
achievements as well as possible future developments of
this exciting field of research, which combines multiple
scientific disciplines and is, like few other areas in chem-
istry, subject to continuous enthusiastic discussion and
compassionate dispute.
Broadly speaking, the main scientific challenges for de
novo drug design are compound scoring (activity predic-
tion, DG estimation), sampling (on-the-fly compound
assembly and navigation in search space), and the synthetic
accessibility of the designs [27]. In their pioneering study
from 1991 [19], Moon and Howe argued that: ‘‘Given
detailed structural knowledge of the target receptor, it
should be possible to construct a model of a potential
ligand, by algorithmic connection of small molecular
fragments, that will exhibit the desired structural and
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electrostatic complementarity with the receptor’’. At the
time, searching the space of candidate compounds was
considered the most critical issue of the design process, and
molecular fragments as building blocks were primarily
used to obtain a manageable search space. This was one
reason for choosing peptides and peptide-mimetics as a
preferred molecule class for exploration. Among the vari-
ous algorithms that have been employed for de novo design
ever since, the methods for navigation in chemical space
probably have diversified the most, ranging from exhaus-
tive product enumeration and deterministic combinatorial
approaches to stochastic sampling by evolutionary algo-
rithms and particle swarms, simulated annealing, and
Markov chains, to name just some of the prominent
examples [26]. By method transfer the field has massively
benefited from parallel developments in computer science
and engineering. Today, visualization of the multi-objec-
tive compound optimization progress and online structure–
activity landscape modeling can be used to observe and
potentially prevent premature convergence or misguided
design runs [28–30]. It is fair to say that one might consider
the task of chemical space navigation solved. With the first
structure-based de novo design study published in 1976
[31, 32], this is mirrored in the continuously increasing
number of successful compound designs that have been
published ever since (Fig. 1).
With few exceptions, the early design methods relied on
static X-ray structures providing the essential structural and
pharmacophoric feature constraints for in situ ligand
assembly. Evidently, rigid models of ligand-accommodating
receptor cavities cannot account for induced or flexible fit
phenomena that may be observed upon fragment binding,
which certainly has contributed to a somewhat curbed
enthusiasm and acceptance of de novo design by the
medicinal chemistry community at the time. Some of the
current molecular design tools explicitly allow for molecular
flexibility, albeit sometimes at the price of strongly increased
needs for computation time. Unrealistic CPU time require-
ment has been an argument repeatedly put forward by
molecular designers when applications were unsuccessful or
too demanding challenges were posed. While this argument
might have been acceptable in the past, it may no longer be
justified in light of continuously increasing capacity of
modern computers. From a technical point of view, it seems
realistic that GPU computing, cloud computing and other
massively distributed hardware solutions will provide the
necessary technological framework enabling sustained pro-
gress in de novo design. Still, we must not forget that our
Fig. 1 Selected computationally de novo designed or motivated
compounds that were synthesized and successfully tested for
bioactivity. 1: FKBP12 inhibitor [51]; 2: HIV-1 protease inhibitor
[52]; 3: thrombin inhibitor [53]; 4: pepsin inhibitor [54]; 5: DNA
gyrase inhibitor [55]; 6: Kv1.5 potassium channel blocker [56]; 7:
CDK4 inhibitor [57, 58]; 8: CYP51 inhibitor [59]; 9: HIV-1 reverse
transcriptase inhibitor [34]; 10: factor Xa inhibitor [60]; 11: HIV-1
protease inhibitor [61]; 12: DHODH inhibitor [62]; 13: HIV-1
reverse transcriptase inhibitor [63]; 14: Tat-TAR interaction inhib-
itor [64]; 15: Estrogen receptor ligand [65]; 16: Cdc25B phosphatase
inhibitor [66]; 17: CB1 inverse agonist [40]; 18: Plk1 type II
inhibitor [67]
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understanding of the physical forces governing ligand-
receptor interaction is incomplete, and gaining a decimal
point in computational precision is meaningless if insuffi-
cient models are used.
With the advent of reaction-driven compound fragmenta-
tion and assembly techniques (e.g. RECAP [33], virtual
organic synthesis approaches like SYNOPSIS [34] or TOPAS
[35]) and fast substructure-based prediction of ‘‘complexity’’
the issue of synthetic feasibility has been partially addressed.
Despite several convincing applications, the accurate com-
puter-based assessment of context-dependent building block
reactivity still remains profoundly challenging—in particular
when rapid estimations for high-throughput applications are
mandatory like in de novo compound construction.
The great importance of using a suitable set of frag-
ments for virtual compound generation is highlighted ex-
emplarily by three selected case studies. The first describes
the design of novel inhibitors of hepatitis C virus (HCV)
helicase. Brancale and coworkers equipped the receptor-
based de novo design software LigBuilder [36] with two
different sets of molecular building blocks, which resulted
in the initial designs A and B, respectively (Fig. 2) [37]. It
is evident that the highly complex compound A is an
attempt to fill the complete binding site, which most likely
is a consequence of poor scoring as larger compounds often
yield better scores. To some degree, such complex struc-
tural suggestions produced by de novo design software
have hampered acceptance of computer-based de novo
design by medicinal chemists in the past. Design B—
despite its nondrug-like structure—might be considered as
a prototype ligand of HCV helicase, which was actually
successfully converted into the chemically feasible inhib-
itor 19 (IC50 = 260 nM). Derivative molecules with such
changes still fit the in silico models but have improved
synthetic accessibility and more desirable physicochemical
properties.
A conceptually related ligand-based approach has been
presented by Feher et al. who used the Evolutionary
Algorithm Inventor (EAI) software together with a topo-
logical pharmacophore model for generating compound
modifications of inhibitors of the gonadotropin releasing
hormone (GnRH) receptor [38]. Basically, the software
suggested scaffolds and their decoration by suitable side-
chains that matched reference pharmacophore models.
Several potent combinatorial variations were synthesized,
one of which (compound 20) exhibited strong antagonistic
activity (Ki = 50 nM) on the GnRH receptor (Fig. 3) [39].
Tight interaction with medicinal chemists proved to be
essential for post hoc candidate selection and building
block prioritization.
A third example of compound optimization from a de
novo designed prototype to a potent lead structure is pre-
sented in Fig. 4. The software TOPAS produced a small
series of structural suggestions that were further optimized
as potent inverse agonists of cannabinoid receptor 1 (CB1)
[40]. A single known reference compound served as a
template for fragment-based virtual ligand assembly, gui-
ded by a topological pharmacophore model (CATS) [41].
One of the initial designs (21) had poor activity (Ki =
1,500 nM) but was chosen for subsequent optimization
Fig. 2 De novo designed inhibitors of hepatitis C virus (HCV)
helicase. Designs A and B were suggested by the software using
different sets of fragments for compound generation. Bioactive
compound 19 was developed from Design B as a starting point for
optimization
Fig. 3 Combinatorial design of GnRH receptor ligands. Several
potent hits were obtained by in silico side-chain optimization
J Comput Aided Mol Des (2012) 26:115–120 117
123
through iterative modeling, synthesis, and testing, which
via intermediate compound 22 (Ki = 13 nM) eventually
led to the benzodioxole 23 (Ki = 4 nM) exhibiting desired
in vivo efficacy [42].
These selected examples confirm that profound chemi-
cal understanding is essential for successful application of
computer-based de novo design tools. One cannot expect
that these software tools deliver potent leads from scratch.
Future drug design tools should incorporate as much
medicinal chemistry knowledge as possible to facilitate
candidate selection and increase their acceptance and uti-
lization for drug discovery.
The greatest remaining challenge is activity prediction—
not just for individual targets but also whole target panels
aiming at polypharmacology predictions guiding automated
computer-based molecular design. Since the early days
fragment growing and linking has become a recurring
scheme pursued by the majority of de novo design approa-
ches. When fragment contributions to the free energy of
ligand-receptor binding are of an approximately additive
enthalpic nature, even computationally demanding methods
may be employed for energy estimation. Despite its appeal
building block additivity cannot be assumed a priori. Irre-
spective of such considerations, we are still far from being
able to reliably estimate entropic contributions to ligand-
receptor complex formation. With few exceptions, scoring
of de novo designed compounds usually ignores or
explicitly avoids attempts of entropy calculation. Here, we
see a massive demand for innovative concepts and approa-
ches before significant progress will be possible for de novo
design. Similar to structure sampling, the field might benefit
from intensified crosstalk and interaction between drug
designers, theoretical chemists and physicists.
‘‘Top-down’’ machine learning models complement the
‘‘bottom-up’’ scoring concepts and have found productive
application in de novo design software. For example, dif-
ferent types of artificial neural networks and kernel-based
regression models have replaced the early QSAR models.
A particular appeal lies in their speed of calculation and
adaptability to new data, without the need for explicit
energy computation. Possibly the machine-learning para-
digm offers a temporary solution to the scoring problem, by
providing ‘‘knowledge-based’’, target-specific models
instead of ‘‘global’’ energy computation. A major limita-
tion of these methods is their need for training data, which
are available in great amounts for massively researched
targets only. The most simplistic approach to compound
scoring is offered by methods based on chemical similarity.
Here, the objective is to maximize similarity between the
de novo designs and reference compound(s) with known
activity. This technique may be considered as similarity
searching in virtual chemical space. Again, the concept
does not apply to novel targets or pockets, but has been
successfully employed for the purpose of scaffold-hopping
and bioisosteric replacement.
We expect immediate progress for receptor-based de
novo design from a combination of flexible pocket models
with advanced methods for shape and pharmacophore
matching. Such a scoring scheme would include extended
pharmacophoric features allowing, e.g., for ‘‘strong’’,
‘‘medium’’ and ‘‘weak’’ hydrogen bridges, better consid-
eration of arene–arene interactions and geometries, as well
as explicit solvent molecules, and would allow for mod-
erate pocket and ligand adaptation during the actual ligand
construction, thereby possibly avoiding artifact ligand
poses [43]. With continuously better scoring functions
available, de novo designed compounds will have a greater
chance of exhibiting the desired activity and property
profile, and due to increased ‘‘chemical attractiveness’’
getting accepted for synthesis.
With high-throughput screening and fragment-based
approaches fuelling today’s drug discovery pipelines,
computer-assisted de novo design plays an increasing role in
this game [25, 44, 45]. It will be most interesting to see how
this situation will develop during the next decade [46–48].
Structural novelty combined with synthetic feasibility might
be more important for a de novo design than actual bioac-
tivity, which can often be increased by means of medicinal
chemistry [49]. In 1987, Sheridan et al. wrote [50]: ‘‘Only a
few novel bond ‘frameworks’ in which important
Fig. 4 De novo designed hCB1 inverse agonists. The original design
(21) was step-wise optimized to become a potent lead structure with
desired in vivo efficacy
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pharmacophore atoms are held in the proper arrangement
need to be found to suggest new areas for drug design and
synthesis.’’ This statement is true today as it was in the early
days of computer-based drug design. The primary aim of de
novo design tools is to fuel the creativity of chemists by
making surprising and innovative suggestions.
Acknowledgments The author is grateful to Hugo Kubinyi for
valuable feedback on the manuscript. This study was supported by the
Swiss National Science Foundation (grant 205321-134783) and the
OPO-Foundation Zurich.
References
1. Gund P, Wipke WT, Langridge R (1974) Computer searching of
a molecular structure file for pharmacophoric patterns. Comput
Chem Res Educ Technol 3:5–21
2. Martin YC, Bures MG, Willett P (1990) Searching databases of
three-dimensional structures. In: Lipkowitz K, Boyd D (eds)
Reviews in computational chemistry, vol 1. VCH, Weinheim,
pp 213–263
3. Sheridan RP, Venkataraghavan R (1987) Designing novel nico-
tinic agonists by searching a database of molecular shapes.
J Comput Aided Mol Des 1:243–256
4. Lewis RA, Dean PM (1989) Automated site-directed drug design:
the formation of molecular templates in primary structure gen-
eration. Proc R Soc Lond B 236:141–162
5. VanDrie JH, Weininger D, Martin YC (1989) ALADDIN: an
integrated tool for computer-assisted molecular design and
pharmacophore recognition from geometric, steric, and sub-
structure searching of three-dimensional molecular structures.
J Comput Aided Mol Des 3:225–240
6. Bartlett PA, Shea GT, Telfer SJ, Waterman S (1989) CAVEAT: a
program to facilitate the structure-derived design of biologically
active molecules. In: Roberts SM (ed) Molecular recognition in
chemical and biological problems, vol 78. Spec Publ R Soc
Chem, Cambridge, pp 182–196
7. Lauri G, Bartlett PA (1994) CAVEAT: a program to facilitate the
design of organic molecules. J Comput Aided Mol Des 8:51–66
8. Carhart RE, Smith DH, Gray NAB, Nourse JG, Djerassi C (1981)
GENOA: a computer program for structure elucidation utilizing
overlapping and alternative substructures. J Org Chem 46:
1708–1718
9. Wise M, Cramer RD, Smith D, Exman I (1983) Progress in three-
dimensional drug design: the use of real time color graphics and
computer postulation of bioactive molecules in DYLOMMS. In:
Dearden JC (ed) Quantitative approaches to drug design. Else-
vier, Amsterdam, pp 145–146
10. Goodford PJ (1995) A computational procedure for determining
energetically favorable binding sites on biologically important
macromolecules. J Med Chem 28:849–857
11. Miranker A, Karplus M (1991) Functionality maps of binding
sites: a multiple copy simultaneous search method. Proteins 11:
29–34
12. Kuntz ID, Blaney JM, Oatley SJ, Langridge R, Ferrin TE (1982)
A geometric approach to macromolecule-ligand interactions.
J Mol Biol 161:269–288
13. Cramer RD, Patterson DE, Bunce JD (1988) Comparative
molecular field analysis (CoMFA). 1. Effect of shape on binding
of steroids to carrier proteins. J Am Chem Soc 110:5959–5967
14. Jackson RC (1995) Update on computer-aided drug design. Curr
Opin Biotechnol 6:646–651
15. Bo¨hm HJ (1996) Current computational tools for de novo ligand
design. Curr Opin Biotechnol 7:433–436
16. Bohacek RS, McMartin C (1997) Modern computational chem-
istry and drug discovery: structure generating programs. Curr
Opin Chem Biol 1:157–161
17. Marrone TJ, Briggs JM, McCammon JA (1997) Structure-based
drug design: computational advances. Annu Rev Pharmacol
Toxicol 37:71–90
18. Kubinyi H (1998) Combinatorial and computational approaches in
structure-based drug design. Curr Opin Drug Discov Devel 1:16–27
19. Moon JB, Howe WJ (1991) Computer design of bioactive mol-
ecules: a method for receptor-based de novo ligand design. Pro-
teins 11:314–328
20. Bohacek RS, McMartin C (1994) Multiple highly diverse struc-
tures complementary to enzyme binding sites: results of extensive
application of a de novo design method incorporating combina-
torial growth. J Am Chem Soc 116:5560–5571
21. Nishibata Y, Itai A (1991) Automatic creation of drug candidate
structures based on receptor structure. Starting point for artificial
lead generation. Tetrahedron 47:8985–8990
22. Nishibata Y, Itai A (1993) Confirmation of usefulness of a
structure construction program based on three-dimensional
receptor structure for rational lead generation. J Med Chem 36:
2921–2928
23. Bo¨hm HJ (1992) The computer program LUDI: a new method for
the de novo design of enzyme inhibitors. J Comput Aided Mol
Des 6:61–78
24. Bo¨hm HJ (1992) LUDI: rule-based automatic design of new
substituents for enzyme inhibitor leads. J Comput Aided Mol Des
6:593–606
25. Loving K, Alberts I, Sherman W (2010) Computational approa-
ches for fragment-based and de novo design. Curr Top Med
Chem 10:14–32
26. Hartenfeller M, Schneider G (2011) Enabling future drug dis-
covery by de novo design. WIREs Comp Mol Sci 1:742–759
27. Schneider G, Fechner U (2005) Computer-based de novo design
of drug-like molecules. Nat Rev Drug Discov 4:649–663
28. Reutlinger M, Guba W, Martin RE, Alanine AI, Hoffmann T,
Klenner A, Hiss JA, Schneider P, Schneider G (2011) Neigh-
borhood-preserving visualization of adaptive structure-activity
landscapes: application to drug discovery. Angew Chem Int Ed
Engl. doi:10.1002/anie.201105156
29. Schneider G, Hartenfeller M, Reutlinger M, Tanrikulu Y, Pros-
chak E, Schneider P (2009) Voyages to the (un)known: adaptive
design of bioactive compounds. Trends Biotechnol 27:18–26
30. Dimova D, Wawer M, Wassermann AM, Bajorath J (2011)
Design of multitarget activity landscapes that capture hierarchical
activity cliff distributions. J Chem Inf Model 51:258–266
31. Beddell CR, Goodford PJ, Norrington FE, Wilkinson S, Wootton
R (1976) Compounds designed to fit a site of known structure in
human haemoglobin. Br J Pharmacol 57:201–209
32. Beddell CR, Goodford PJ, Stammers DK, Wootton R (1979)
Species differences in the binding of compounds designed to fit a
site of known structure in adult human haemoglobin. Br J Phar-
macol 65:535–543
33. Lewell XQ, Judd DB, Watson SP, Hann MM (1998) RECAP—
retrosynthetic combinatorial analysis procedure: a powerful new
technique for identifying privileged molecular fragments with
useful applications in combinatorial chemistry. J Chem Inf
Comput Sci 38:511–522
34. Vinkers HM, de Jonge MR, Daeyaert FF, Heeres J, Koymans
LM, van Lenthe JH, Lewi PJ, Timmerman H, Van Aken K,
Janssen PA (2003) SYNOPSIS: synthesize and optimize system
in silico. J Med Chem 46:2765–2773
35. Schneider G, Lee ML, Stahl M, Schneider P (2000) De novo
design of molecular architectures by evolutionary assembly of
J Comput Aided Mol Des (2012) 26:115–120 119
123
drug-derived building blocks. J Comput Aided Mol Des 14:
487–494
36. Wang R, Gao Y, Lai L (2000) LigBuilder: a multi-purpose pro-
gram for structure-based drug design. J Mol Model 6:498–516
37. Kandil S, Biondaro S, Vlachakis D, Cummins AC, Coluccia A,
Berry C, Leyssen P, Neyts J, Brancale A (2009) Discovery of a
novel HCV helicase inhibitor by a de novo drug design approach.
Bioorg Med Chem Lett 19:2935–2937
38. Feher M, Gao Y, Baber JC, Shirley WA, Saunders J (2008) The use
of ligand-based de novo design for scaffold hopping and sidechain
optimization: two case studies. Bioorg Med Chem 16:422–427
39. Lanier MC, Feher M, Ashweek NJ, Loweth CJ, Rueter JK, Slee
DH, Williams JP, Zhu YF, Sullivan SK, Brown MS (2007)
Selection, synthesis, and structure-activity relationship of tetra-
hydropyrido[4, 3-d]pyrimidine-2, 4-diones as human GnRH
receptor antagonists. Bioorg Med Chem 15:5590–5603
40. Rogers-Evans M, Alanine A, Bleicher K, Kube D, Schneider G
(2004) Identification of novel cannabinoid receptor ligands via
evolutionary de novo design and rapid parallel synthesis. QSAR
Comb Sci 26:426–430
41. Schneider G, Neidhart W, Giller T, Schmid G (1999) ‘Scaffold-
hopping’ by topological pharmacophore search: a contribution to
virtual screening. Angew Chem Int Ed Engl 38:2894–2896
42. Alig L, Alsenz J, Andjelkovic M, Bendels S, Be´nardeau A,
Bleicher K, Bourson A, David-Pierson P, Guba W, Hildbrand S,
Kube D, Lu¨bbers T, Mayweg AV, Narquizian R, Neidhart W,
Nettekoven M, Plancher JM, Rocha C, Rogers-Evans M, Ro¨ver S,
Schneider G, Taylor S, Waldmeier P (2008) Benzodioxoles:
novel cannabinoid-1 receptor inverse agonists for the treatment of
obesity. J Med Chem 51:2115–2127
43. Bissantz C, Kuhn B, Stahl M (2010) A medicinal chemist’s guide
to molecular interactions. J Med Chem 53:5061–5084
44. Mauser H, Guba W (2008) Recent developments in de novo design
and scaffold hopping. Curr Opin Drug Discov Devel 11:365–374
45. Langdon SR, Ertl P, Brown N (2010) Bioisosteric replacement
and scaffold hopping in lead generation and optimization. Mol Inf
29:366–385
46. Bailey D, Brown D (2001) High-throughput chemistry and
structure-based design: survival of the smartest. Drug Discov
Today 6:57–59
47. Bleicher KH, Bo¨hm HJ, Mu¨ller K, Alanine AI (2003) Hit and
lead generation: beyond high-throughput screening. Nat Rev
Drug Discov 2:369–378
48. Schneider G (2010) Virtual screening: an endless staircase? Nat
Rev Drug Discov 9:273–276
49. Kru¨ger BA, Dietrich A, Baringhaus KH, Schneider G (2009)
Scaffold-hopping potential of fragment-based de novo design: the
chances and limits of variation. Comb Chem High Throughput
Screen 12:383–396
50. Sheridan RP, Rusinko A III, Nilakantan R, Venkataraghavan R
(1989) Searching for pharmacophores in large coordinate data bases
and its use in drug design. Proc Natl Acad Sci USA 86:8165–8169
51. Babine RE, Bleckman TM, Kissinger CR, Showalter R, Pelletier
LA, Lewis C, Tucker K, Moomaw E, Parge HE, Villafranca JE
(1995) Design, synthesis and X-ray crystallographic studies of
novel FKBB-12 ligands. Bioorg Med Chem Lett 5:1719–1724
52. Reich SH, Melnick M, Davies JF II, Appelt K, Lewis KK, Fuhry
MA, Pino M, Trippe AJ, Nguyen D, Dawson H, Wu BW, Musick
L, Kosa M, Kahil D, Webber S, Gehlhaar DK, Andrada D, Shetty
B (1995) Protein structure-based design of potent orally bio-
available, nonpeptide inhibitors of human immunodeficiency
virus protease. Proc Natl Acad Sci USA 92:3298–3302
53. Bo¨hm HJ, Banner DW, Weber L (1999) Combinatorial docking
and combinatorial chemistry: design of potent non-peptide
thrombin inhibitors. J Comput Aided Mol Des 13:51–56
54. Ripka AS, Satyshur KA, Bohacek RS, Rich DH (2001) Aspartic
protease inhibitors designed from computer-generated templates
bind as predicted. Org Lett 3:2309–2312
55. Bo¨hm HJ, Boehringer M, Bur D, Gmuender H, Huber W, Klaus
W, Kostrewa D, Kuehne H, Luebbers T, Meunier-Keller N,
Mueller F (2000) Novel inhibitors of DNA gyrase: 3D structure
based biased needle screening, hit validation by biophysical
methods, and 3D guided optimization. A promising alternative to
random screening. J Med Chem 43:2664–2674
56. Schneider G, Cle´ment-Chomienne O, Hilfiger L, Schneider P,
Kirsch S, Bo¨hm HJ, Neidhart W (2000) Virtual screening for
bioactive molecules by evolutionary de novo design. Angew
Chem Int Ed Engl 39:4130–4133
57. Honma T, Hayashi K, Aoyama T, Hashimoto N, Machida T,
Fukasawa K, Iwama T, Ikeura C, Ikuta M, Suzuki-Takahashi I,
Iwasawa Y, Hayama T, Nishimura S, Morishima H (2001)
Structure-based generation of a new class of potent Cdk4 inhib-
itors: new de novo design strategy and library design. J Med
Chem 44:4615–4627
58. Honma T, Yoshizumi T, Hashimoto N, Hayashi K, Kawanishi N,
Fukasawa K, Takaki T, Ikeura C, Ikuta M, Suzuki-Takahashi I,
Hayama T, Nishimura S, Morishima H (2001) A novel approach
for the development of selective Cdk4 inhibitors: library design
based on locations of Cdk4 specific amino acid residues. J Med
Chem 44:4628–4640
59. Ji H, Zhang W, Zhang M, Kudo M, Aoyama Y, Yoshida Y,
Sheng C, Song Y, Yang S, Zhou Y, Lu¨ J, Zhu J (2003) Structure-
based de novo design, synthesis, and biological evaluation of
non-azole inhibitors specific for lanosterol 14alpha-demethylase
of fungi. J Med Chem 46:474–485
60. Liebeschuetz JW, Jones SD, Morgan PJ, Murray CW, Rimmer
AD, Roscoe JM, Waszkowycz B, Welsh PM, Wylie WA, Young
SC, Martin H, Mahler J, Brady L, Wilkinson K (2002) PRO_-
SELECT: combining structure-based drug design and array-based
chemistry for rapid lead discovery. 2. The development of a
series of highly potent and selective factor Xa inhibitors. J Med
Chem 45:1221–1232
61. Pierce AC, Rao G, Bemis GW (2004) BREED: generating novel
inhibitors through hybridization of known ligands application to
CDK2, P38, and HIV protease. J Med Chem 47:2768–2775
62. Davies M, Heikkila¨ T, McConkey GA, Fishwick CW, Parsons MR,
Johnson AP (2009) Structure-based design, synthesis, and char-
acterization of inhibitors of human and Plasmodium falciparum
dihydroorotate dehydrogenases. J Med Chem 52:2683–2693
63. Jorgensen WL, Ruiz-Caro J, Tirado-Rives J, Basavapathruni A,
Anderson KS, Hamilton AD (2006) Computer-aided design of
non-nucleoside inhibitors of HIV-1 reverse transcriptase. Bioorg
Med Chem Lett 16:663–667
64. Schu¨ller A, Suhartono M, Fechner U, Tanrikulu Y, Breitung S,
Scheffer U, Go¨bel MW, Schneider G (2008) The concept of
template-based de novo design from drug-derived molecular
fragments and its application to TAR RNA. J Comput Aided Mol
Des 22:59–68
65. Firth-Clark S, Kirton SB, Willems HM, Williams A (2008) De
novo ligand design to partially flexible active sites: application of
the ReFlex algorithm to carboxypeptidase A, acetylcholinester-
ase, and the estrogen receptor. J Chem Inf Model 48:296–305
66. Park H, Bahn YJ, Ryu SE (2009) Structure-based de novo design
and biochemical evaluation of novel Cdc25 phosphatase inhibi-
tors. Bioorg Med Chem Lett 19:4330–4334
67. Schneider G, Geppert T, Hartenfeller M, Reisen F, Klenner A,
Reutlinger M, Ha¨hnke V, Hiss JA, Zettl H, Keppner S, Spa¨nkuch
B, Schneider P (2011) Reaction-driven de novo design, synthesis
and testing of potential type II kinase inhibitors. Future Med
Chem 3:415–424
120 J Comput Aided Mol Des (2012) 26:115–120
123
